Eniola's computational neuroscience and pharmacology profile, her HFSP-adjacent interdisciplinary positioning (ODE/Bayesian/TDA pharmacology bridging biology and mathematics), and her documented collaborations with Berridge, Gershman, Daw, and Mattar make her research narrative genuinely competitive — but only after a doctoral degree is in hand. If any of the 47 listed programmes admit pre-PhD researchers (specifically IDRC Research Awards, IFS Research Grants, and AAS/AESA early-career tracks which sometimes extend to advanced independent researchers), Eniola should frame her CCT model as applied to an African addiction burden problem, lean into her LMIC independent-researcher status, and cite her Zenodo/OSF preprints and the Bayesian validation as evidence of doctoral-equivalent output. For programmes that require doctoral completion, the strategic move is to use this application cycle to identify host supervisors and draft proposals now, so applications are submission-ready the moment her PhD enrolment begins in Graz (Oct 2026).